Peter Greenleaf, Aurinia CEO (OS Therapies)
A little biotech's second crack at dry eye disease comes up short. And this time there will be no extra shot at success
You can add Aurinia to the list of biotechs which followed mixed Phase II data right over the late-stage cliff.
The biotech was hammered after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
